Evidence map›Paper›PMID 39301338›Full record

ReviewCureus2024

Myocarditis Induced by Immune Checkpoint Inhibitors: An Exploratory Review.

Esteban Zavaleta-Monestel, Jonathan García-Montero, Adriana Anchía-Alfaro, Carolina Rojas-Chinchilla, Ricardo Quesada-Villaseñor, Sebastián Arguedas-Chacón, Monserrat Barrantes-López, Paula Molina-Sojo, Andrea Zovi, Carlos Zúñiga-Orlich

Abstract readReview
In one paragraph

Review in Cureus, 2024. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. The role of exosomes in bladder cancer immunotherapy.Journal of the National Cancer Center · 2025
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors.

Esteban Zavaleta-MonestelPharmacy, Hospital Clínica Bíblica, San José, CRI.
Jonathan García-MonteroPharmacy and Clinical Research, Hospital Clínica Bíblica, San José, CRI.
Adriana Anchía-AlfaroResearch, Hospital Clínica Bíblica, San José, CRI.
Carolina Rojas-ChinchillaPharmacy, Hospital Clínica Bíblica, San José, CRI.
Ricardo Quesada-VillaseñorResearch, Hospital Clínica Bíblica, San José, CRI.
Sebastián Arguedas-ChacónPharmacy and Clinical Research, Hospital Clínica Bíblica, San José, CRI.
Monserrat Barrantes-LópezFaculty of Pharmacy, Universidad de Iberoamérica, San José, CRI.
Paula Molina-SojoFaculty of Pharmacy, Universidad de Iberoamérica, San José, CRI.
Andrea ZoviHygiene, Food Safety, and Nutrition, Ministry of Health, Rome, ITA.
Carlos Zúñiga-OrlichOncology, Hospital Clínica Bíblica, San José, CRI.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Checkpoints are essential proteins in the immune system that regulate the intensity and duration of immune responses, preventing damage to healthy tissues during the fight against pathogens and abnormal cells. While these mechanisms are crucial in cancer defense, this disease can alter the functionality of these proteins. This is why checkpoint inhibitors have emerged as an important class of drugs to potentiate the antitumor immune response. However, it has been observed that these drugs can trigger adverse effects, among which myocarditis is one of the most prevalent. This article explores the signaling pathways associated with checkpoint inhibitors, their adverse effects, and their impact on the development of myocarditis, as well as potential therapeutic strategies.

Indexed as

antibodies monoclonalcancercheckpoint inhibitorsimmune systemimmunotherapymyocarditis

Identifiers

PMID39301338
PMCPMC11412606

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.